Form 4: Acrivon Therapeutics Chief Legal Officer Acquires Stock Options

Acrivon Therapeutics' Chief Legal Officer, Mary Miller, was granted stock options for 67,567 shares on March 1, 2024.

Summary

• Mary Miller, the Chief Legal Officer of Acrivon Therapeutics, was granted stock options to purchase 67,567 shares of common stock.
• The options have an exercise price of $5.70 per share.
• The options vest over time, with 25% vesting on March 1, 2025, and the remaining 75% vesting in 36 equal monthly installments thereafter.
• The vesting is contingent upon Ms. Miller's continued employment with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The granting of stock options aligns the interests of the Chief Legal Officer with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Risks

• The value of the stock options is dependent on the future performance of Acrivon Therapeutics' stock price.
• If Ms. Miller leaves the company before the options fully vest, she may forfeit some or all of the unvested options.

Future Outlook

The stock options will vest over time, contingent on the continued service of the Chief Legal Officer.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 25% after one year and the remainder over 36 months is a typical vesting structure.
• The exercise price of $5.70 is a common practice to be set at or near the market price at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Legal Officer to contribute to the company's success.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates

Keywords

stock options, Acrivon Therapeutics, insider trading, executive compensation, vesting, equity